These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16815579)

  • 1. Engineered chloroplasts as vaccine factories to combat bioterrorism.
    Streatfield SJ
    Trends Biotechnol; 2006 Aug; 24(8):339-42. PubMed ID: 16815579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a subunit vaccine against Bacillus anthracis.
    Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
    Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selected research problems of anthrax vaccine development].
    Zakowska D; Kocik J; Bartoszcze M
    Przegl Epidemiol; 2009; 63(4):505-12. PubMed ID: 20120948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of an anthrax DNA vaccine with electroporation.
    Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
    Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of Functionally Active and Immunogenic Non-Glycosylated Protective Antigen from Bacillus anthracis in Nicotiana benthamiana by Co-Expression with Peptide-N-Glycosidase F (PNGase F) of Flavobacterium meningosepticum.
    Mamedov T; Chichester JA; Jones RM; Ghosh A; Coffin MV; Herschbach K; Prokhnevsky AI; Streatfield SJ; Yusibov V
    PLoS One; 2016; 11(4):e0153956. PubMed ID: 27101370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines: countering anthrax: vaccines and immunoglobulins.
    Grabenstein JD
    Clin Infect Dis; 2008 Jan; 46(1):129-36. PubMed ID: 18171228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge.
    Koya V; Moayeri M; Leppla SH; Daniell H
    Infect Immun; 2005 Dec; 73(12):8266-74. PubMed ID: 16299323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
    Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
    Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
    Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.
    Keitel WA
    Expert Rev Vaccines; 2006 Aug; 5(4):417-30. PubMed ID: 16989623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
    Gupta M; Alam S; Bhatnagar R
    Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Past, imminent and future human medical countermeasures for anthrax.
    Baillie LW
    J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.
    Bouzianas DG
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of anthrax DNA vaccines.
    Ferrari ME; Hermanson G; Rolland A
    Curr Opin Mol Ther; 2004 Oct; 6(5):506-12. PubMed ID: 15537052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro screen of bioinformatically selected Bacillus anthracis vaccine candidates by coupled transcription, translation, and immunoprecipitation analysis.
    Gat O; Grosfeld H; Shafferman A
    Methods Mol Biol; 2007; 375():211-33. PubMed ID: 17634604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of a recombinant bacterial lipoprotein in higher plant chloroplasts.
    Glenz K; Bouchon B; Stehle T; Wallich R; Simon MM; Warzecha H
    Nat Biotechnol; 2006 Jan; 24(1):76-7. PubMed ID: 16327810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced vaccine antigen delivery by Salmonella using antibiotic-free operator-repressor titration-based plasmid stabilisation compared to chromosomal integration.
    Leckenby MW; Spear AM; Neeson BN; Williamson ED; Cranenburgh RM; Atkins HS
    Microb Pathog; 2009 Apr; 46(4):201-6. PubMed ID: 19490834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
    Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
    Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.
    Fasanella A; Tonello F; Garofolo G; Muraro L; Carattoli A; Adone R; Montecucco C
    Vaccine; 2008 Oct; 26(45):5684-8. PubMed ID: 18775462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.